Gilead and Glympse Bio will test whether synthetic biomarkers can show how badly damaged patients' livers are. It's a partnership that hints at the biotech's commitment to NASH.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,